CD274 and cancer: We validated the results of an identification conducted within a large pooled population: 1,125 patients with whole-exome sequencing (WES) data across seven cancer types; 792 patients treated with anti-PD-(L)1 therapy in 10 independent cohorts and 333 patients from The Cancer Genome Atlas (TCGA) database (Supplementary Data 1).